Epicatechin limits renal injury by mitochondrial protection in cisplatin nephropathy

Katsuyuki Tanabe, Yoshifuru Tamura, Miguel A. Lanaspa, Makoto Miyazaki, Norihiko Suzuki, Waichi Sato, Yohei Maeshima, George F. Schreiner, Francisco J. Villarreal, Richard J. Johnson, Takahiko Nakagawa

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Cisplatin nephropathy can be regarded as a mitochondrial disease. Intervention to halt such deleterious injury is under investigation. Recently, the flavanol (-)-epicatechin emerges as a novel compound to protect the cardiovascular system, owing in part to mitochondrial protection. Here, we have hypothesized that epicatechin prevents the progression of cisplatininduced kidney injury by protecting mitochondria. Epicatechin was administered 8 h after cisplatin injury was induced in the mouse kidney. Cisplatin significantly induced renal dysfunction and tubular injury along with an increase in oxidative stress. Mitochondrial damages were also evident as a decrease in loss of mitochondrial mass with a reduction in the oxidative phosphorylation complexes and low levels of MnSOD. The renal damages and mitochondrial injuries were significantly prevented by epicatechin treatment. Consistent with these observations, an in vitro study using cultured mouse proximal tubular cells demonstrated that cisplatin-induced mitochondrial injury, as revealed by a decrease in mitochondrial succinate dehydrogenase activity, an induction of cytochrome c release, mitochondrial fragmentation, and a reduction in complex IV protein, was prevented by epicatechin. Such a protective effect of epicatechin might be attributed to decreased oxidative stress and reduced ERK activity. Finally, we confirmed that epicatechin did not perturb the anticancer effect of cisplatin in HeLa cells. In conclusion, epicatechin exhibits protective effects due in part to its ability to prevent the progression of mitochondrial injury in mouse cisplatin nephropathy. Epicatechin may be a novel option to treat renal disorders associated with mitochondrial dysfunction.

Original languageEnglish
JournalAmerican Journal of Physiology - Renal Physiology
Volume303
Issue number9
DOIs
Publication statusPublished - Nov 1 2012
Externally publishedYes

Fingerprint

Catechin
Cisplatin
Kidney
Wounds and Injuries
Oxidative Stress
Mitochondrial Diseases
Succinate Dehydrogenase
Oxidative Phosphorylation
Cardiovascular System
Cytochromes c
HeLa Cells
Mitochondria

Keywords

  • AKI
  • Cocoa
  • Complex IV
  • Dark chocolate
  • MnSOD

ASJC Scopus subject areas

  • Physiology
  • Urology

Cite this

Epicatechin limits renal injury by mitochondrial protection in cisplatin nephropathy. / Tanabe, Katsuyuki; Tamura, Yoshifuru; Lanaspa, Miguel A.; Miyazaki, Makoto; Suzuki, Norihiko; Sato, Waichi; Maeshima, Yohei; Schreiner, George F.; Villarreal, Francisco J.; Johnson, Richard J.; Nakagawa, Takahiko.

In: American Journal of Physiology - Renal Physiology, Vol. 303, No. 9, 01.11.2012.

Research output: Contribution to journalArticle

Tanabe, K, Tamura, Y, Lanaspa, MA, Miyazaki, M, Suzuki, N, Sato, W, Maeshima, Y, Schreiner, GF, Villarreal, FJ, Johnson, RJ & Nakagawa, T 2012, 'Epicatechin limits renal injury by mitochondrial protection in cisplatin nephropathy', American Journal of Physiology - Renal Physiology, vol. 303, no. 9. https://doi.org/10.1152/ajprenal.00227.2012
Tanabe, Katsuyuki ; Tamura, Yoshifuru ; Lanaspa, Miguel A. ; Miyazaki, Makoto ; Suzuki, Norihiko ; Sato, Waichi ; Maeshima, Yohei ; Schreiner, George F. ; Villarreal, Francisco J. ; Johnson, Richard J. ; Nakagawa, Takahiko. / Epicatechin limits renal injury by mitochondrial protection in cisplatin nephropathy. In: American Journal of Physiology - Renal Physiology. 2012 ; Vol. 303, No. 9.
@article{18893af66e784ae9912098e1bb48266e,
title = "Epicatechin limits renal injury by mitochondrial protection in cisplatin nephropathy",
abstract = "Cisplatin nephropathy can be regarded as a mitochondrial disease. Intervention to halt such deleterious injury is under investigation. Recently, the flavanol (-)-epicatechin emerges as a novel compound to protect the cardiovascular system, owing in part to mitochondrial protection. Here, we have hypothesized that epicatechin prevents the progression of cisplatininduced kidney injury by protecting mitochondria. Epicatechin was administered 8 h after cisplatin injury was induced in the mouse kidney. Cisplatin significantly induced renal dysfunction and tubular injury along with an increase in oxidative stress. Mitochondrial damages were also evident as a decrease in loss of mitochondrial mass with a reduction in the oxidative phosphorylation complexes and low levels of MnSOD. The renal damages and mitochondrial injuries were significantly prevented by epicatechin treatment. Consistent with these observations, an in vitro study using cultured mouse proximal tubular cells demonstrated that cisplatin-induced mitochondrial injury, as revealed by a decrease in mitochondrial succinate dehydrogenase activity, an induction of cytochrome c release, mitochondrial fragmentation, and a reduction in complex IV protein, was prevented by epicatechin. Such a protective effect of epicatechin might be attributed to decreased oxidative stress and reduced ERK activity. Finally, we confirmed that epicatechin did not perturb the anticancer effect of cisplatin in HeLa cells. In conclusion, epicatechin exhibits protective effects due in part to its ability to prevent the progression of mitochondrial injury in mouse cisplatin nephropathy. Epicatechin may be a novel option to treat renal disorders associated with mitochondrial dysfunction.",
keywords = "AKI, Cocoa, Complex IV, Dark chocolate, MnSOD",
author = "Katsuyuki Tanabe and Yoshifuru Tamura and Lanaspa, {Miguel A.} and Makoto Miyazaki and Norihiko Suzuki and Waichi Sato and Yohei Maeshima and Schreiner, {George F.} and Villarreal, {Francisco J.} and Johnson, {Richard J.} and Takahiko Nakagawa",
year = "2012",
month = "11",
day = "1",
doi = "10.1152/ajprenal.00227.2012",
language = "English",
volume = "303",
journal = "American Journal of Physiology - Renal Physiology",
issn = "0363-6127",
publisher = "American Physiological Society",
number = "9",

}

TY - JOUR

T1 - Epicatechin limits renal injury by mitochondrial protection in cisplatin nephropathy

AU - Tanabe, Katsuyuki

AU - Tamura, Yoshifuru

AU - Lanaspa, Miguel A.

AU - Miyazaki, Makoto

AU - Suzuki, Norihiko

AU - Sato, Waichi

AU - Maeshima, Yohei

AU - Schreiner, George F.

AU - Villarreal, Francisco J.

AU - Johnson, Richard J.

AU - Nakagawa, Takahiko

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Cisplatin nephropathy can be regarded as a mitochondrial disease. Intervention to halt such deleterious injury is under investigation. Recently, the flavanol (-)-epicatechin emerges as a novel compound to protect the cardiovascular system, owing in part to mitochondrial protection. Here, we have hypothesized that epicatechin prevents the progression of cisplatininduced kidney injury by protecting mitochondria. Epicatechin was administered 8 h after cisplatin injury was induced in the mouse kidney. Cisplatin significantly induced renal dysfunction and tubular injury along with an increase in oxidative stress. Mitochondrial damages were also evident as a decrease in loss of mitochondrial mass with a reduction in the oxidative phosphorylation complexes and low levels of MnSOD. The renal damages and mitochondrial injuries were significantly prevented by epicatechin treatment. Consistent with these observations, an in vitro study using cultured mouse proximal tubular cells demonstrated that cisplatin-induced mitochondrial injury, as revealed by a decrease in mitochondrial succinate dehydrogenase activity, an induction of cytochrome c release, mitochondrial fragmentation, and a reduction in complex IV protein, was prevented by epicatechin. Such a protective effect of epicatechin might be attributed to decreased oxidative stress and reduced ERK activity. Finally, we confirmed that epicatechin did not perturb the anticancer effect of cisplatin in HeLa cells. In conclusion, epicatechin exhibits protective effects due in part to its ability to prevent the progression of mitochondrial injury in mouse cisplatin nephropathy. Epicatechin may be a novel option to treat renal disorders associated with mitochondrial dysfunction.

AB - Cisplatin nephropathy can be regarded as a mitochondrial disease. Intervention to halt such deleterious injury is under investigation. Recently, the flavanol (-)-epicatechin emerges as a novel compound to protect the cardiovascular system, owing in part to mitochondrial protection. Here, we have hypothesized that epicatechin prevents the progression of cisplatininduced kidney injury by protecting mitochondria. Epicatechin was administered 8 h after cisplatin injury was induced in the mouse kidney. Cisplatin significantly induced renal dysfunction and tubular injury along with an increase in oxidative stress. Mitochondrial damages were also evident as a decrease in loss of mitochondrial mass with a reduction in the oxidative phosphorylation complexes and low levels of MnSOD. The renal damages and mitochondrial injuries were significantly prevented by epicatechin treatment. Consistent with these observations, an in vitro study using cultured mouse proximal tubular cells demonstrated that cisplatin-induced mitochondrial injury, as revealed by a decrease in mitochondrial succinate dehydrogenase activity, an induction of cytochrome c release, mitochondrial fragmentation, and a reduction in complex IV protein, was prevented by epicatechin. Such a protective effect of epicatechin might be attributed to decreased oxidative stress and reduced ERK activity. Finally, we confirmed that epicatechin did not perturb the anticancer effect of cisplatin in HeLa cells. In conclusion, epicatechin exhibits protective effects due in part to its ability to prevent the progression of mitochondrial injury in mouse cisplatin nephropathy. Epicatechin may be a novel option to treat renal disorders associated with mitochondrial dysfunction.

KW - AKI

KW - Cocoa

KW - Complex IV

KW - Dark chocolate

KW - MnSOD

UR - http://www.scopus.com/inward/record.url?scp=84868369214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868369214&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00227.2012

DO - 10.1152/ajprenal.00227.2012

M3 - Article

C2 - 22933302

AN - SCOPUS:84868369214

VL - 303

JO - American Journal of Physiology - Renal Physiology

JF - American Journal of Physiology - Renal Physiology

SN - 0363-6127

IS - 9

ER -